|1.||Arisawa, Hirohiko: 4 articles (01/2002 - 01/2002)|
|2.||Fukui, Kenji: 4 articles (01/2002 - 01/2002)|
|3.||Masunaga, Hiroaki: 4 articles (01/2002 - 01/2002)|
|4.||Chambers, Mark S: 3 articles (08/2012 - 07/2007)|
|5.||Fujise, Nobuaki: 3 articles (01/2002 - 01/2002)|
|6.||Fisher, Abraham: 2 articles (01/2008 - 08/2002)|
|7.||Vitti, Robert: 2 articles (12/2007 - 07/2007)|
|8.||Armstrong, Ingrid: 2 articles (12/2007 - 07/2007)|
|9.||Jones, Christopher Uwe: 2 articles (12/2007 - 07/2007)|
|10.||Biel, Merrill A: 2 articles (12/2007 - 07/2007)|
01/01/2002 - "In these studies, cevimeline 30mg three times daily increased salivary flow and improved the symptoms of xerostomia in a significantly higher percentage of patients compared with placebo. "
11/19/1997 - "These results indicate that SNI-2011 may be useful in the treatment of xerostomia because of its long-lasting sialogogic action."
11/01/1994 - "These results suggest that SNI-2011 could be useful in the treatment of xerostomia in patients with Sjögren's syndrome."
01/01/2002 - " clinical efficacy of cevimeline in relieving symptoms of xerostomia, including oral dryness and difficulties in chewing, swallowing and speaking, has been demonstrated by placebo-controlled, double-blind, randomised clinical trials in the USA and Japan. "
04/01/2008 - "The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study."
|2.||Sjogren's Syndrome (Sjogren Syndrome)
01/01/2008 - "Moreover, cevimeline significantly improved the salivary flow rate in patients with Sjogren's syndrome. "
01/01/2008 - "Several well designed placebo-controlled trials demonstrated that 4-12 weeks' therapy with cevimeline 30 mg three times daily improved symptoms of dry mouth in patients with Sjogren's syndrome. "
01/01/2008 - "Increased salivary flow was maintained in the longer term with cevimeline in patients with Sjogren's syndrome and symptoms of dry mouth, according to the results of an open-label 52-week study. "
01/01/2008 - "Oral cevimeline 30 mg three times daily was generally well tolerated in patients with Sjogren's syndrome, with many of the most commonly reported adverse events reflecting the pharmacological action of the drug."
01/01/2008 - "Cevimeline is an orally administered muscarinic receptor agonist that is indicated for the treatment of symptoms of dry mouth in patients with Sjogren's syndrome. "
04/01/2008 - "Cevimeline hydrochloride, a specific agonist of the M3 muscarinic receptor, is beneficial in the treatment of symptoms of xerostomia and xerophthalmia associated with Sjögren's syndrome (SS). "
11/01/1998 - "We investigated effects of (+/-)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride), a rigid analogue of acetylcholine, on saliva and tear secretions in rats and mice to evaluate its therapeutical efficacy for xerostomia and xerophthalmia in patients with Sjogren's syndrome and X-ray exposure in the head and neck. "
|4.||Head and Neck Neoplasms (Head and Neck Cancer)
12/01/2007 - "A total of 255 adults with head-and-neck cancer who had received more than 40 Gy of radiation 4 months or more before entry and had clinically significant salivary gland dysfunction received cevimeline hydrochloride 45 mg t.i.d. "
12/01/2007 - "To assess the safety of long-term cevimeline treatment of radiation-induced xerostomia in patients with head-and-neck cancer; and to assess the efficacy of cevimeline in these patients. "
07/15/2007 - "Cevimeline for the treatment of postirradiation xerostomia in patients with head and neck cancer."
07/15/2007 - "To study the efficacy and safety of cevimeline in two double-blind trials (Studies 003 and 004) enrolling patients with head and neck cancer in whom xerostomia developed after radiotherapy. "
07/15/2007 - "Cevimeline was well tolerated by patients with xerostomia after radiotherapy for head and neck cancer, and oral administration of 30-45 mg of cevimeline three times daily increased unstimulated salivary flow."
03/01/2002 - "To evaluate the safety and efficacy of 2 dosages of cevimeline for the treatment of xerostomia and keratoconjunctivitis sicca in patients with Sjögren's syndrome. "
03/01/2002 - "A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca."
|3.||Muscarinic Receptors (Muscarinic Acetylcholine Receptor)
|5.||Immunologic Factors (Immunomodulators)
|6.||Muscarinic M1 Receptor
|7.||Muscarinic M3 Receptor
|3.||Palliative Care (Palliative Medicine)